UNITED NATIONS ENVIRONMENT PROGRAMME
INTERNATIONAL LABOUR ORGANISATION
WORLD HEALTH ORGANIZATION
INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY
ENVIRONMENTAL HEALTH CRITERIA 217
BACILLUS THURINGIENSIS
This report contains the collective views of an international group of
experts and does not necessarily represent the decisions or the stated
policy of the United Nations Environment Programme, the International
Labour Organisation, or the World Health Organization.
Environmental Health Criteria 217
Microbial Pest Control Agent
BACILLUS THURINGIENSIS
Published under the joint sponsorship of the United Nations
Environment Programme, the International Labour Organisation, and the
World Health Organization, and produced within the framework of the
Inter-Organization Programme for the Sound Management of Chemicals.
World Health Organization
Geneva, 1999
The International Programme on Chemical Safety (IPCS),
established in 1980, is a joint venture of the United Nations
Environment Programme (UNEP), the International Labour Organisation
(ILO), and the World Health Organization (WHO). The overall
objectives of the IPCS are to establish the scientific basis for
assessment of the risk to human health and the environment from
exposure to chemicals, through international peer review processes, as
a prerequisite for the promotion of chemical safety, and to provide
technical assistance in strengthening national capacities for the
sound management of chemicals.
The Inter-Organization Programme for the Sound Management of
Chemicals (IOMC) was established in 1995 by UNEP, ILO, the Food and
Agriculture Organization of the United Nations, WHO, the United
Nations Industrial Development Organization, the United Nations
Institute for Training and Research, and the Organisation for Economic
Co-operation and Development (Participating Organizations), following
recommendations made by the 1992 UN Conference on Environment and
Development to strengthen cooperation and increase coordination in the
field of chemical safety. The purpose of the IOMC is to promote
coordination of the policies and activities pursued by the
Participating Organizations, jointly or separately, to achieve the
sound management of chemicals in relation to human health and the
environment.
WHO Library Cataloguing-in-Publication Data
Bacillus thuringiensis.
(Environmental health criteria ; 217)
1.Bacillus thuringinesis - pathogenicity 2.Pest control,
Biological - methods 3.Insecticides - chemistry
4.Environmental exposure 5.Occupational exposure
I.Series
ISBN 92 4 157217 5 (NLM Classification: QW 127.5.B2)
ISSN 0250-863X
The World Health Organization welcomes requests for permission to
reproduce or translate its publications, in part or in full.
Applications and enquiries should be addressed to the Office of
Publications, World Health Organization, Geneva, Switzerland, which
will be glad to provide the latest information on any changes made to
the text, plans for new editions, and reprints and translations
already available.
(c) World Health Organization 1999
Publications of the World Health Organization enjoy copyright
protection in accordance with the provisions of Protocol 2 of the
Universal Copyright Convention. All rights reserved.
The designations employed and the presentation of the material in
this publication do not imply the expression of any opinion whatsoever
on the part of the Secretariat of the World Health Organization
concerning the legal status of any country, territory, city, or area
or of its authorities, or concerning the delimitation of its frontiers
or boundaries.
The mention of specific companies or of certain manufacturers'
products does not imply that they are endorsed or recommended by the
World Health Organization in preference to others of a similar nature
that are not mentioned. Errors and omissions excepted, the names of
proprietary products are distinguished by initial capital letters.
CONTENTS
ENVIRONMENTAL HEALTH CRITERIA FOR BACILLUS THURINGIENSIS
PREAMBLE
ABBREVIATIONS
1. SUMMARY
1.1. Identity, biological characteristics, and
analytical methods
1.2. Mode of action on target insects
1.3. Habitats
1.4. Commercial products, production and application
1.5. Effects of Bt on non-target organisms
1.6. Exposure and effects of Bt on humans
1.7. Conclusions
2. IDENTITY, BIOLOGICAL PROPERTIES, AND ANALYTICAL METHODS
2.1. Identity
2.1.1. Bacillus thuringiensis (Bt)
2.1.2. Relationship between Bacillus thuringiensis and
Bacillus cereus
2.1.3. Crystal composition and morphology
2.1.4. Classification of Bt subspecies
2.1.5. Genetics of ICP
2.1.6. Beta-exotoxin
2.1.7. Other Bt metabolites
2.2. Bioassays
2.2.1. Spore counts
2.2.2. International bioassay for ICPs
3. MODE OF ACTION ON TARGET INSECTS
3.1. Bioactivity of field isolates
3.2. Mechanism of action of Bt formulations
3.3. Resistance of insect populations
4. NATURAL AND TREATED HABITATS
4.1. Natural occurrence of Bt
4.1.1. Bt in insect hosts
4.1.2. Bt in soil
4.1.3. Bt on plant surfaces
4.2. Treated habitats
4.3. Environmental fate, distribution and movement
4.3.1. Distribution and fate of Bt in terrestrial
habitats
4.3.1.1 Fate of Bt and ICP on plant surfaces
4.3.1.2 Fate of Bt in soil
4.3.2. Distribution and fate of Bt in aquatic habitats
4.3.3. Transport of Bt by non-target organisms
5. COMMERCIAL PRODUCTION
5.1. History of Bt and its commercial applications
5.1.1. Production levels
5.1.2. Production processes, formulations and quality
standards
5.1.3. General patterns of use
5.1.3.1 Applications in agriculture and forestry
5.1.3.2 Applications in vector control
6. EFFECTS ON ANIMALS
6.1. Mammals
6.1.1. Oral exposure
6.1.2. Inhalation exposure
6.1.3. Dermal exposure
6.1.4. Dermal scarification exposure
6.1.5. Subcutaneous inoculation
6.1.6. Ocular exposure
6.1.7. Intraperitoneal exposure
6.1.7.1 Immune-intact animals
6.1.7.2 Immune-suppressed animals
6.1.8. Effects of activated Bt ICP
6.1.9. Studies in wild animals
6.2. Effects on birds
6.3. Effects on aquatic vertebrates
6.4. Effects on invertebrates
6.4.1. Effects on invertebrates other than insects
6.4.2. Effects on non-target insects
6.4.2.1 Aquatic insects
6.4.2.2 Terrestrial insects
6.4.2.3 Honey-bees
6.4.2.4 Parasitoids
7. EXPOSURE AND EFFECTS ON HUMANS
7.1. Bacillus thuringiensis
7.1.1. Experimental exposure of humans
7.1.2. Exposure of workers during manufacture
7.1.3. Exposure of workers in spraying operations
7.1.4. Exposure of human populations by spraying
operations over populated areas.
7.1.5. Clinical case reports
7.1.6. Dietary exposure of the general population
7.2. Bacillus cereus
8. EVALUATION OF HUMAN HEALTH RISKS AND EFFECTS ON THE ENVIRONMENT
9. CONCLUSIONS AND RECOMMENDATIONS
10. PREVIOUS EVALUATIONS BY INTERNATIONAL ORGANISATIONS
REFERENCES
RÉSUMÉ
RESUMEN
NOTE TO READERS OF THE CRITERIA MONOGRAPHS
Every effort has been made to present information in the criteria
monographs as accurately as possible without unduly delaying their
publication. In the interest of all users of the Environmental Health
Criteria monographs, readers are requested to communicate any errors
that may have occurred to the Director of the International Programme
on Chemical Safety, World Health Organization, Geneva, Switzerland, in
order that they may be included in corrigenda.
* * *
A detailed data profile and a legal file can be obtained from the
International Register of Potentially Toxic Chemicals, Case postage
356, 1219 Châtelaine, Geneva, Switzerland (telephone no. + 41 22 -
9799111, fax no. + 41 22 - 7973460, E-mail irptc@unep.ch).
* * *
This publication was made possible by grant number
5 U01 ES02617-15 from the National Institute of Environmental Health
Sciences, National Institutes of Health, USA, and by financial support
from the European Commission.
Environmental Health Criteria
PREAMBLE
Objectives
In 1973 the WHO Environmental Health Criteria Programme was
initiated with the following objectives:
(i) to assess information on the relationship between exposure
to environmental pollutants and human health, and to provide
guidelines for setting exposure limits;
(ii) to identify new or potential pollutants;
(iii) to identify gaps in knowledge concerning the health effects
of pollutants;
(iv) to promote the harmonization of toxicological and
epidemiological methods in order to have internationally
comparable results.
The first Environmental Health Criteria (EHC) monograph, on
mercury, was published in 1976 and since that time an ever-increasing
number of assessments of chemicals and of physical effects have been
produced. In addition, many EHC monographs have been devoted to
evaluating toxicological methodology, e.g., for genetic, neurotoxic,
teratogenic and nephrotoxic effects. Other publications have been
concerned with epidemiological guidelines, evaluation of short-term
tests for carcinogens, biomarkers, effects on the elderly and so
forth.
Since its inauguration the EHC Programme has widened its scope,
and the importance of environmental effects, in addition to health
effects, has been increasingly emphasized in the total evaluation of
chemicals.
The original impetus for the Programme came from World Health
Assembly resolutions and the recommendations of the 1972 UN Conference
on the Human Environment. Subsequently the work became an integral
part of the International Programme on Chemical Safety (IPCS), a
cooperative programme of UNEP, ILO and WHO. In this manner, with the
strong support of the new partners, the importance of occupational
health and environmental effects was fully recognized. The EHC
monographs have become widely established, used and recognized
throughout the world.
The recommendations of the 1992 UN Conference on Environment and
Development and the subsequent establishment of the Intergovernmental
Forum on Chemical Safety with the priorities for action in the six
programme areas of Chapter 19, Agenda 21, all lend further weight to
the need for EHC assessments of the risks of chemicals.
Scope
The criteria monographs are intended to provide critical reviews
on the effect on human health and the environment of chemicals and of
combinations of chemicals and physical and biological agents. As such,
they include and review studies that are of direct relevance for the
evaluation. However, they do not describe every study carried out.
Worldwide data are used and are quoted from original studies, not from
abstracts or reviews. Both published and unpublished reports are
considered and it is incumbent on the authors to assess all the
articles cited in the references. Preference is always given to
published data. Unpublished data are only used when relevant published
data are absent or when they are pivotal to the risk assessment. A
detailed policy statement is available that describes the procedures
used for unpublished proprietary data so that this information can be
used in the evaluation without compromising its confidential nature
(WHO (1990) Revised Guidelines for the Preparation of Environmental
Health Criteria Monographs. PCS/90.69, Geneva, World Health
Organization).
In the evaluation of human health risks, sound human data,
whenever available, are preferred to animal data. Animal and
in vitro studies provide support and are used mainly to supply
evidence missing from human studies. It is mandatory that research on
human subjects is conducted in full accord with ethical principles,
including the provisions of the Helsinki Declaration.
The EHC monographs are intended to assist national and
international authorities in making risk assessments and subsequent
risk management decisions. They represent a thorough evaluation of
risks and are not, in any sense, recommendations for regulation or
standard setting. These latter are the exclusive purview of national
and regional governments.
Content
The layout of EHC monographs for chemicals is outlined below.
* Summary -- a review of the salient facts and the risk evaluation
of the chemical
* Identity -- physical and chemical properties, analytical methods
* Sources of exposure
* Environmental transport, distribution and transformation
* Environmental levels and human exposure
* Kinetics and metabolism in laboratory animals and humans
* Effects on laboratory mammals and in vitro test systems
* Effects on humans
* Effects on other organisms in the laboratory and field
* Evaluation of human health risks and effects on the environment
* Conclusions and recommendations for protection of human health
and the environment
* Further research
* Previous evaluations by international bodies, e.g., IARC, JECFA,
JMPR
Selection of chemicals
Since the inception of the EHC Programme, the IPCS has organized
meetings of scientists to establish lists of priority chemicals for
subsequent evaluation. Such meetings have been held in: Ispra, Italy,
1980; Oxford, United Kingdom, 1984; Berlin, Germany, 1987; and North
Carolina, USA, 1995. The selection of chemicals has been based on the
following criteria: the existence of scientific evidence that the
substance presents a hazard to human health and/or the environment;
the possible use, persistence, accumulation or degradation of the
substance shows that there may be significant human or environmental
exposure; the size and nature of populations at risk (both human and
other species) and risks for environment; international concern, i.e.
the substance is of major interest to several countries; adequate data
on the hazards are available.
If an EHC monograph is proposed for a chemical not on the
priority list, the IPCS Secretariat consults with the Cooperating
Organizations and all the Participating Institutions before embarking
on the preparation of the monograph.
Procedures
The order of procedures that result in the publication of an EHC
monograph is shown in the flow chart. A designated staff member of
IPCS, responsible for the scientific quality of the document, serves
as Responsible Officer (RO). The IPCS Editor is responsible for layout
and language. The first draft, prepared by consultants or, more
usually, staff from an IPCS Participating Institution, is based
initially on data provided from the International Register of
Potentially Toxic Chemicals, and reference data bases such as Medline
and Toxline.
The draft document, when received by the RO, may require an
initial review by a small panel of experts to determine its scientific
quality and objectivity. Once the RO finds the document acceptable as
a first draft, it is distributed, in its unedited form, to well over
150 EHC contact points throughout the world who are asked to comment
on its completeness and accuracy and, where necessary, provide
additional material. The contact points, usually designated by
governments, may be Participating Institutions, IPCS Focal Points, or
individual scientists known for their particular expertise. Generally
some four months are allowed before the comments are considered by the
RO and author(s). A second draft incorporating comments received and
approved by the Director, IPCS, is then distributed to Task Group
members, who carry out the peer review, at least six weeks before
their meeting.
The Task Group members serve as individual scientists, not as
representatives of any organization, government or industry. Their
function is to evaluate the accuracy, significance and relevance of
the information in the document and to assess the health and
environmental risks from exposure to the chemical. A summary and
recommendations for further research and improved safety aspects are
also required. The composition of the Task Group is dictated by the
range of expertise required for the subject of the meeting and by the
need for a balanced geographical distribution.
The three cooperating organizations of the IPCS recognize the
important role played by nongovernmental organizations.
Representatives from relevant national and international associations
may be invited to join the Task Group as observers. While observers
may provide a valuable contribution to the process, they can only
speak at the invitation of the Chairperson. Observers do not
participate in the final evaluation of the chemical; this is the sole
responsibility of the Task Group members. When the Task Group
considers it to be appropriate, it may meet in camera.
All individuals who as authors, consultants or advisers
participate in the preparation of the EHC monograph must, in addition
to serving in their personal capacity as scientists, inform the RO if
at any time a conflict of interest, whether actual or potential, could
be perceived in their work. They are required to sign a conflict of
interest statement. Such a procedure ensures the transparency and
probity of the process.
When the Task Group has completed its review and the RO is
satisfied as to the scientific correctness and completeness of the
document, it then goes for language editing, reference checking, and
preparation of camera-ready copy. After approval by the Director,
IPCS, the monograph is submitted to the WHO Office of Publications for
printing. At this time a copy of the final draft is sent to the
Chairperson and Rapporteur of the Task Group to check for any errors.
It is accepted that the following criteria should initiate the
updating of an EHC monograph: new data are available that would
substantially change the evaluation; there is public concern for
health or environmental effects of the agent because of greater
exposure; an appreciable time period has elapsed since the last
evaluation.
All Participating Institutions are informed, through the EHC
progress report, of the authors and institutions proposed for the
drafting of the documents. A comprehensive file of all comments
received on drafts of each EHC monograph is maintained and is
available on request. The Chairpersons of Task Groups are briefed
before each meeting on their role and responsibility in ensuring that
these rules are followed.
WHO TASK GROUP ON ENVIRONMENTAL HEALTH CRITERIA FOR BACILLUS
THURINGIENSIS
Members
Professor D. Calamari, Department of Biology, Structure and Function,
University of Milan, Varese, Italy
Dr C. Cummins, Institute of Terrestrial Ecology, Monks Wood, Abbots
Ripton, Huntingdon, Cambridgeshire, United Kingdom
Dr N. Gratz, Commugny, Switzerland (Rapporteur)
Dr A. Klier, Unité de Biochimie Microbienne, Département des
Biotechnologies, Institut Pasteur, Paris, France
Professor P. Lüthy, Microbiological Institute ETH, Zurich, Switzerland
Dr C.M. Scanlan, Texas A & M University, Department of Veterinary
Pathobiology, Texas Veterinary Medical Center, Texas, USA (Chairman)
Observers
Dr R.J. Cibulsky, Abbott Laboratories, Chemical and Agricultural
Products, North Chicago, Illinois, USA
Dr E. Cozzi, Clinical Research and Development, Animal Health
Products, Abbott Laboratories, North Chicago, Illinois, USA
Dr M. Ronchin, International Centre for Pesticide Safety, Busto
Garolfo, Milan, Italy
Secretariat
Professor M. Maroni, International Centre for Pesticide Safety, Busto
Garolfo, Milan, Italy
Dr R. Plestina, Zagreb, Croatia
ENVIRONMENTAL HEALTH CRITERIA FOR BACILLUS THURINGIENSIS
A WHO Task Group on Environmental Health Criteria for the
microbial pest control agent Bacillus thuringiensis (Bt) met at the
International Centre for Pesticide Safety in Busto Garolfo, Milan,
Italy, from 27 to 31 October 1997. Professor M. Maroni, Director of
the Centre, welcomed participants on behalf of the Centre, which was
responsible for organizing the meeting. Dr R. Plestina, IPCS temporary
adviser, opened the meeting and welcomed participants on behalf of Dr
M. Mercier, Director of IPCS. The Group reviewed and revised the draft
and made an evaluation of the risks for human health and the
environment from exposure to Bt products. Drs R. Plestina and A. Aitio
of the IPCS Central Unit were responsible for the scientific aspects
of the monograph, and Dr P.G. Jenkins for the editing. The assistance
of manufacturers, notably Abbott Laboratories, in providing
unpublished documentation for the review is greatly appreciated.
Microbial Pest Control Agents (MPCAs), notably products of
various Bt subspecies, are increasingly used in pest management
programmes against the larvae of several insect pests of major
agricultural crops and forests, and several insect vectors of human
diseases, and some nuisance pests. Bt products have been used
worldwide, and their commercial production is about 1% of that of
chemical pesticides. A number of reviews have recently been published
on various aspects of Bt (Entwistle et al., 1983; McClintock et al.,
1995; Cannon, 1996; Dean et al., 1996; Kumar et al., 1996; Schnepf et
al., 1998; Nielsen-LeRoux et al., 1998).
The activities in preparing this document were recommended by an
Informal Consultation on the Safety of Microbial Pest Control Agents
held in Geneva in June 1993. The first draft of the monograph was
prepared by a drafting group in 1994 and was subsequently amended by
Professor C.M. Scanlan (Texas A&M University, Department of Veterinary
Pathobiology, The Texas Veterinary Medical Center, Texas, USA). The
revised draft was circulated to the IPCS contact points. Based on the
comments received, it was amended and updated by Drs B.M. Hansen and
N.B. Hendriksen (National Environmental Research Institute, Roskilde,
Denmark). The document was finally approved by the Task Group members.
ABBREVIATIONS
Bc Bacillus cereus
Bt Bacillus thuringiensis
Bta Bacillus thuringiensis subspecies aizawai
Btd Bacillus thuringiensis subspecies darmstadiensis
Bte Bacillus thuringiensis subspecies entomocidus
Btg Bacillus thuringiensis subspecies galleriae
Bti Bacillus thuringiensis subspecies israelensis
Btk Bacillus thuringiensis subspecies kurstaki
Btko Bacillus thuringiensis subspecies konkukian
Btt Bacillus thuringiensis subspecies thuringiensis
Btte Bacillus thuringiensis subspecies tenebrionis
cfu colony forming unit
GILSP good industrial large-scale practice
GMO genetically modified organism
HPLC high-performance liquid chromatography
ICP insecticidal crystal protein
ITU international toxic unit
IUPAC International Union of Pure and Applied Chemistry
MPCA microbial pest control agent
NTO non-target organism
PCR polymerase chain reaction
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
1. SUMMARY
This monograph deals with microbial pest control agents (MCPAs)
based on Bacillus thuringiensis (Bt). This bacterium is also a key
source of genes for transgenic expression to provide pest resistance
in plants and microorganisms as pest control agents in so-called
genetically modified organisms (GMOs). The potential effects on human
health and the environment of GMOs involve several aspects that are
only remotely or not at all related to Bt products, and they are
therefore outside the scope of this monograph.
1.1 Identity, biological characteristics and analytical methods
Bt is a facultative anaerobic, gram-positive bacterium that forms
characteristic protein inclusions adjacent to the endospore. Bt
subspecies can synthesize more than one parasporal inclusion. Bt is
genetically indistinguishable from Bc, except for the ability of Bt to
produce parasporal crystalline inclusions, which are toxic for certain
invertebrates, especially species of insect larvae belonging to the
insect orders Coleoptera, Diptera and Lepidoptera. The
parasporal inclusions are formed by different insecticidal crystal
proteins (ICP). The crystals have various shapes (bipyramidal,
cuboidal, flat rhomboid, spherical or composite with two crystal
types), depending on their ICP composition. A partial correlation
between crystal morphology, ICP composition, and bioactivity against
target insects has been established.
The basic phenotypic taxon is the subspecies, identified by the
flagellar (H) serotype. By 1998, 67 subspecies had been described. The
genes that encode the ICPs are mostly on plasmids. Each ICP is the
product of a single gene. Most plasmids with ICP genes are readily
transferred by conjugation between Bt strains and may be transferred
to related species of bacteria. The phenotypic classification has now
been complemented by molecular biological characterization, based on
the sequence of the crystal (cry and cyt) genes rather than target
organism specificity. Different domains of the ICP are responsible for
host susceptibility (receptor recognition) and toxicity (pore
formation).
Techniques commonly used to characterize Bt strains or the ICP
itself include cell wall fatty acid analysis, monoclonal antibodies,
oligonucleotide DNA probes, plasmid profiles, polymerase chain
reaction (PCR) analysis, DNA fingerprinting and SDS-PAGE profiles.
Beta-exotoxin, a heat-stable nucleotide, is produced by some Bt
subspecies during vegetative growth and may contaminate the products.
Beta-exotoxin is toxic for almost all forms of life including humans
and the target insect orders. During vegetative growth, various Bt
strains produce an assortment of antibiotics, enzymes, metabolites and
toxins, including Bc toxins, that may have detrimental effects on both
target organisms and non-target organisms (NTOs). Spore counts do not
accurately reflect the insecticidal activity of a Bt strain or Bt
product. The potency (ITU/mg) of each Bt product is bioassayed using
an international standard that uses a specific test insect.
1.2 Mode of action on target insects
The sporulated Bt with ICP or spore-ICP complexes must be
ingested by a susceptible insect larva. The efficacy of the ICP
depends on the solubilization in the midgut, the conversion of the
protoxin to the biologically active toxin by proteolytic enzymes,
specific membrane receptor binding by the C-terminal domain of the
active toxin, and pore formation by the N-terminal domain with
subsequent lysis of the epithelial cells. Spore germination and
proliferation of the vegetative cells into the haemocoel may result in
a septicaemia, contributing to the cause of death. Receptor binding by
the ICP is the major determinant of host specificity by the different
Bt ICPs.
1.3 Habitats
Many different Bt subspecies have been isolated from dead or
dying insects mostly from the orders Coleoptera, Diptera and
Lepidoptera, but many subspecies have also been isolated from soil,
leaf surfaces and other habitats. The carcasses of dead insects often
contain large quantities of spores and ICPs that may enter the
environment. The coleopteran-active and lepidopteran-active Bt
subspecies are primarily associated with the soil and phylloplane
(leaf surfaces), whereas the dipteran-active Bt subspecies are
commonly found in aquatic environments. In the environment, the spores
persist and vegetative growth may occur when conditions are favourable
and nutrients are available.
1.4 Commercial products, production and application
Conventional Bt products, which utilize naturally-occurring Bt
strains, account for approximately 90% of the world MPCA market. Most
Bt products contain ICP and viable spores, but in some Bti products
the spores are inactivated. Each year some 13 000 tonnes are produced
using aerobic fermentation technology. Conventional Bt products have
been targeted primarily against lepidopteran pests of agricultural and
forestry crops; however in recent years, Bt strains active against
coleopteran pests have also been marketed. Strains of Bti active
against dipteran vectors of parasitic and viral diseases are being
used in public health programmes.
Commercial Bt formulations may be applied as an insecticide to
foliage, soil, water environments or food storage facilities. After
the application of a Bt subspecies to an ecosystem, the vegetative
cells and spores may persist at gradually decreasing concentrations
for weeks, months or years as a component of the natural microflora.
The ICPs, however, are rendered biologically inactive within hours or
days.
1.5 Effects of Bt on non-target organisms
Studies on mammals, particularly those on laboratory animals,
have evaluated possible infectivity and toxicity of various Bt
preparations, which include the ICPs, vegetative cells and spores. The
ICPs, spores and vegetative cells of the Bt subspecies, which were
administered by different routes, were mostly non-pathogenic and
non-toxic to the various animal species tested. The vegetative cells
and/or spores of Bt were demonstrated to persist for weeks without
causing adverse effects. Bt has not been observed to adversely affect
birds, fish or many other non-target aquatic vertebrates tested in a
large number of laboratory and field studies. Relatively few species
of aquatic invertebrates are susceptible to Bt under either laboratory
or field conditions. Bt does not adversely affect earthworms.
The Bt subspecies have generally been shown to be highly specific
in their insecticidal activity for Coleoptera, Diptera and
Lepidoptera and have demonstrated little, if any, direct toxicity to
non-target arthropods. Most of the existing safety data on non-target
arthropods has been generated using the Bt subspecies with activity
against Diptera and Lepidoptera.
Studies of Bti formulations free of toxic contaminants have not
demonstrated deleterious effects on the vast majority of non-target
arthropods. Some midges (Diptera: Chironomidae), which are closely
related to mosquitos, have been shown to be susceptible to high
dosages of Bti, but are not affected by mosquito larvicidal dosages.
In field studies, transient decreases or increases in populations of
some non-target arthropods have been reported.
Many insect orders have been tested in either the laboratory or
field, most of which have shown no effect from Btk.
Mortality has been observed in honey-bees (Apis mellifera)
after exposure to vegetatively growing Btt and Btk, but the effect
does not seem to be related to spores or ICPs. In laboratory and field
studies Btg demonstrated no adverse effect on honey-bees.
Bte strains that produce beta-exotoxin have been shown to have
adverse effects on non-target arthropods.
1.6 Exposure and effects of Bt on humans
The field application of Bt products can result in considerable
aerosol and dermal exposure of workers. Agricultural uses of Bt can
result in Bt contamination of potable water and food. With the
exception of case reports on ocular and dermal irritation, no adverse
health effects have been documented after occupational exposure to Bt
products. Human volunteers ingested and inhaled large quantities of a
Btk formulation but experienced no adverse health effects. Antibody
titres to the vegetative cells, spores and spore-crystal complexes
have been demonstrated in workers who spray Bt products; however, no
adverse health effects were reported. There have been some case
reports on the occurrence of Bt in patients with different infectious
diseases. However, none of these studies unequivocally demonstrates an
actual risk to human health from the use of Bt. Bt has not been
reported to cause adverse effects on human health when present in
drinking-water or food.
1.7 Conclusions
Owing to their specific mode of action, Bt products are unlikely
to pose any hazard to humans or other vertebrates or to the great
majority of non-target invertebrates provided that they are free from
non-Bt microorganisms and biologically active products other than the
ICPs. Bt products may be safely used for the control of insect pests
of agricultural and horticultural crops as well as forests. They are
also safe for use in aquatic environments including drinking-water
reservoirs for the control of mosquito, black fly and nuisance insect
larvae. However, it should be noted that vegetative Bt has the
potential for the production of Bc-like toxins, the significance of
which as a cause of human disease is not known.
2. IDENTITY, BIOLOGICAL PROPERTIES, AND ANALYTICAL METHODS
2.1 Identity
Commercial Bacillus thuringiensis (Bt) products are microbial
pest control agents (MPCAs) containing specific insecticidal
crystalline proteins (ICPs) and most often living spores as well as
formulating agents. They are processed fermentation products.
2.1.1 Bacillus thuringiensis
Bt is a facultative anaerobic, motile, gram-positive,
spore-forming bacterium. The formation of parasporal crystals adjacent
to the endospore during sporulation stages III to IV distinguishes Bt
from other Bacillus species.
Bt, like other Bacillus species, has been classified on the
basis of its cellular, cultural, biochemical and genetic
characteristics (Baumann et al., 1984; Claus & Berkley, 1986; Slepecky
& Hemphill, 1992; Carlson & Kolsto, 1993; Hansen et al., 1998). In
1958, Heimpel & Angus (1958) introduced a classification scheme to
identify these crystalliferous bacteria based on their morphological
and biochemical characteristics. However recent molecular analysis
shows that several variations can be found within serotypes, and that
specific biochemical characteristics do not always refer to a specific
serotype (Helgason et al., 1998; Hansen et al., 1998).
2.1.2 Relationship between Bacillus thuringiensis and Bacillus cereus
Bt is a member of the Bc group, which also contains Bacillus
cereus (Bc), B. mycoides and B. anthracis. Furthermore, the
psychrotolerant B. weihenstephanensis has recently been proposed as
a new member of the group (Lechner et al., 1998). Bt can only be
distinguished from Bc by the production during the sporulation process
of one or more inclusion bodies, which have been found to be toxic for
invertebrates, primarily insect species in the orders Coleoptera,
Diptera and Lepidoptera (de Barjac, 1981b; Andrews et al., 1987).
Several studies have been dedicated to a comparison of Bt and Bc on
the basis of characters not related to the production of ICPs
(Hendriksen & Hansen, 1998). Phenotypic differentiation of Bt and Bc
is not possible on the basis of morphology or utilization of organic
compounds (Baumann et al., 1984; Logan & Berkeley, 1984; Priest et
al., 1988), characterization of cell content of fatty acids (Väisänen
et al., 1991) or sugars (Wunschel et al., 1994), multilocus enzyme
electrophoresis (Zahner et al., 1989; Carlson et al., 1994),
enterotoxin production (Damgaard et al., 1996a; Hansen & Hendriksen,
1997a), or serological- and phage-typing techniques (Ohba & Aizawa,
1978; 1986; Väisänen et al., 1991; Murakami et al., 1993; Ahmed et
al., 1995). Likewise, genotypic differentiation of Bt and Bc is not
possible by DNA homology analysis (Kaneko et al., 1978), ribotyping
(Priest et al., 1994; Demezas & Bell, 1995), 16S rDNA sequencing (Ash
et al., 1991); analysis of the 16S-23S internal transcribed sequence
(Wunschel et al., 1994; Bourque et al., 1995), PCR analysis of genes
encoding Bc-like toxic products (Damgaard et al., 1996b; Asano et al.,
1997; Hansen & Hendriksen, 1997b) or pulsed field gel electrophoresis
(Carlson & Kolsto, 1993; Carlson et al., 1994). Giffel et al. (1997)
found differences in 16S rDNA sequences between a limited number Bt
and Bc. Beattie et al. (1998) were able to discriminate among members
of the Bc group by Fourier transform infrared spectroscopy, and
Brousseau et al. (1992) were able to distinguish Bt and Bc by random
amplified polymorphic DNA fingerprinting. However, the transfer of ICP
encoding plasmids from Bt to Bc makes the receptor Bc
indistinguishable from Bt, and vice versa (González et al., 1981,
1982).
2.1.3 Crystal composition and morphology
The existence of parasporal inclusions in Bt was first noted in
1915 (Berliner, 1915), but their protein composition was not
delineated until the 1950s (Angus, 1954). Hannay (1953) detected the
crystalline fine structure that is a property of most of the
parasporal inclusions. Bt subspecies can synthesize more than one
inclusion, which may contain different ICPs. ICPs have also been
called delta endotoxins; however, since the term endotoxin usually
refers to toxins associated with the outer membranes of gram-negative
bacteria, comprising a core lipopoplysaccharide, lipid A and somatic
(O) antigens, this term is not used in this monograph. Depending on
their ICP composition, the crystals have various forms (bipyramidal,
cuboidal, flat rhomboid, or a composite with two or more crystal
types). A partial correlation between crystal morphology, ICP
composition, and bioactivity against target insects has been
established (Bulla et al., 1977; Höfte & Whiteley, 1989; Lynch &
Baumann, 1985).
2.1.4 Classification of Bt subspecies
The classification of Bt subspecies based on the serological
analysis of the flagella (H) antigens was introduced in the early
1960s (de Barjac & Bonnefoi, 1962). This classification by serotype
has been supplemented by morphological and biochemical criteria (de
Barjac, 1981a). Until 1977, only 13 Bt subspecies had been described,
and at that time all subspecies were toxic to Lepidopteran larvae
only. The discovery of other subspecies toxic to Diptera (Goldberg &
Margalit, 1977), Coleoptera (Krieg et al., 1983) and apparently
Nematoda (Narva et al., 1991) enlarged the host range and markedly
increased the number of subspecies. Up to the end of 1998, over 67
subspecies based on flagellar H-serovars had been identified (Table
1). Updated lists of the serovarieties can be obtained from the
reference centre of the Pasteur Institute in Paris (Unité des
Bactéries Entomopathogčnes, Institut Pasteur, Paris, France).
Table 1. Current classification of 67 Bacillus thuringiensis subspecies based
on their flagellar (H) antigensa
Flagellar antigens B. thuringiensis Flagellar antigens B. thuringiensis
subspecies subspecies
1 thuringiensis 28a, 28c jegathesan
2 finitimus 29 amagiensis
3a, 3c alesti 30 medellin
3a, 3b, 3c kurstaki 31 toguchini
3a, 3d sumiyoshiensis 32 cameroun
3a, 3d, 3e fukuokaensis 33 leesis
4a, 4b sotto 34 konkukian
4a, 4c kenyae 35 seoulensis
5a, 5c galleriae 36 malaysiensis
5a, 5c canadensis 37 anadalousiensis
6 entomocidus 38 oswaldocruzi
7 aizawai 39 brasiliensis
8a, 8b morrisoni 40 huazhongensis
8a, 8c ostriniae 41 sooncheon
8b, 8d nigeriensis 42 jinghongiensis
9 tolworthi 43 guiyanguebsus
10a, 10b darmstadiensis 44 higo
10a, 10c londrina 45 roskildiensis
11a, 11b toumanoffi 46 chanpaisis
11a, 11c kyushuensis 47 wratislaviensis
12 thompsoni 48 balearica
13 pakistani 49 muju
14 israelensis 50 navarrensis
15 dakota 51 xiaguangiensis
16 indiana 52 kim
17 tohokuensis 53 asturiensis
18a, 18b kumamotoensis 54 poloniensis
18a, 18c yosoo 55 palmanyolensis
19 tochigiensis 56 rongseni
20a, 20b yunnanensis 57 pirenaica
20a, 20c pondicheriensis 58 argentinensis
21 colmeri 59 iberica
22 shandongiensis 60 pingluonsis
23 japonensis 61 sylvestriensis
24a, 24b neoleonensis 62 zhaodongensis
24a, 24c novosibirsk 63 bolivia
25 coreanensis 64 azorensis
26 silo 65 pulsiensis
27 mexicanensis 66 gracioensis
28a, 28b monterrey 67 vazensis
a Data provided by the Unité des Bactéries Entomopathogčnes, Institut Pasteur,
Paris, France
Crystal serology has shown that a particular crystal type may be
produced by more than one H-serovar (Krywienczyk et al., 1978; Smith,
1987).
2.1.5 Genetics of ICP
In the early 1980s, it was established that most genes coding for
the ICPs reside on large transmissible plasmids, of which most are
readily exchanged between strains by conjugation (González & Carlton,
1980; González et al., 1981). Since these initial studies, numerous
ICP genes have been cloned, sequenced and used to construct Bt strains
with novel insecticidal spectra (Höfte & Whiteley, 1989).
The currently known crystal (cry) gene types encode ICPs that
are specific to either Lepidoptera (cryI), Diptera and
Lepidoptera (cryII), Coleoptera (cryIII), Diptera (cryIV),
or Coleoptera and Lepidoptera (cryV) (Höfte & Whiteley, 1989).
A separate designation is used for the cytolytic (cyt) genes that
encode a nonspecific cytolytic factor, present in Bti ICP and some
other Bt subspecies. However, due to the increasing number of
characterized ICP genes and inconsistencies in the existing cry gene
nomenclature, which is based on insecticidal spectrum, Crickmore et
al. (1998) proposed a new nomenclature based on ICP gene sequences.
The new cry genes are listed in Tables 2 and 3, and Table 4 is a
conversion list from old to new cry gene names. Current
identification of Bt employs both the identity of the cry genes,
which define the host range, and the H-serovars, which define the
subspecies, and recently DNA fingerprinting has been used for further
characterization of subspecies (Hansen et al., 1998).
The ICP gene sequences provided the basis for the construction of
gene-specific probes to screen established Bt strains by hybridization
and PCR analysis for the presence of known nucleotide sequences, and
for characterizing the ICPs from new Bt isolates (Prefontaine et al.,
1987; Juarez-Perez et al., 1997; Bravo et al., 1998; Shevelev et al.,
1998). These studies have permitted the distinction of numerous
subclasses of ICP genes based on sequence homology and toxicity
spectra of the encoded proteins.
All ICPs described to date attack the insect gut upon ingestion
(see chapter 3). To date, each of the proteolytically activated ICP
molecules with insecticidal activity has a variable C-terminal domain,
which is responsible for receptor recognition (host susceptibility),
and a conserved N-terminal domain, which induces pore formation
(toxicity) (Li et al., 1991).
Most naturally occurring Bt strains contain ICPs active against a
single order of insects. However, conjugative transfer between Bt
strains or related species can occur, resulting in new strains with
various plasmid contents. Thus the mobility of the cry genes and the
exchange of plasmids may explain the diverse and complex activity
Table 2. Bacillus thuringiensis crystal protein genes (Crickmore et al., 1998)
Name Acc No Reference Journal Coding
Cry1aa1 M11250 Schnepf et al., 1985 JBC 260 6264-6272 527-4054
Cry1aa2 M10917 Shibano et al., 1985 Gene 34 243-251 153->2955
Cry1aa3 D00348 Shimizu et al., 1988 ABC 52 1565-1573 73-3603
Cry1aa4 X13535 Masson et al., 1989 NAR 17 446-446 1-3528
Cry1aa5 D17518 Udayasuriyan et al., 1994 BBB 58 830-835 81-3611
Cry1aa6 U43605 Masson et al., 1994 Mol Micro 14 851-860 1->1860
Cry1aa7 AF081790 Osman, 1998 unpublished
Cry1aa8 I26149 Liu, 1996 USP 5556784 148-3675
Cry1ab1 M13898 Wabiko et al., 1986 DNA 5 305-314 142-3606
Cry1ab2 M12661 Thorne et al., 1986 J Bact 166 801-811 155-3625
Cry1ab3 M15271 Geiser et al., 1986 Gene 48 109-118 156-3623
Cry1ab4 D00117 Kondo et al., 1987 ABC 51 455-463 163-3630
Cry1ab5 X04698 Hofte et al., 1986 EJB 161 273-280 141-3605
Cry1ab6 M37263 Hefford et al., 1987 J Biotech 6 307-322 73-3540
Cry1ab7 X13233 Haider & Ellar, 1988 NAR 16 10927-10927 1-3465
Cry1ab8 M16463 Oeda et al., 1987 Gene 53 113-119 157-3624
Cry1ab9 X54939 Chak & Jen, 1993 PNSCRC 17 7-14 73-3540
Cry1ab10 A29125 Fischhoff et al., 1987 Bio/technology peptide seq
5 807-813
Cry1ab11 I12419 Ely & Tippett, 1995 USP 5424409 73-
Cry1ab12 AF057670 Silva-Werneck et al., 1998 unpublished 41-3505
Cry1ac1 M11068 Adang et al., 1985 Gene 36 289-300 388-3921
Cry1ac2 M35524 Von Tersch et al., 1991 AEM 57 349-358 239-3772
Cry1ac3 X54159 Dardenne et al., 1990 NAR 18 5546-5546 339->2192
Cry1ac4 M73249 Payne et al., 1991 USP 4990332 1-3537
Cry1ac5 M73248 Payne et al., 1992 USP 5135867 1-3534
Cry1ac6 U43606 Masson et al., 1994 Mol Micro 14 851-860 1->1821
Cry1ac7 U87793 Herrera et al., 1994 AEM 60 682-690 976-4512
Cry1ac8 U87397 Omolo et al., 1997 Curr Micro 34 118-121 153-3686
Cry1ac9 U89872 Gleave et al., 1992 NZJCHS 20 27-36 388-3921
Cry1ac10 AJ002514 Sun & Yu, 1997 unpublished 388-3921
Cry1ac11 AJ130970 Makhdoom & Riazuddin, 1998 unpublished 156-3689
Cry1ac12 I12418 Ely & Tippett, 1995 USP 5424409 81->2990
Cry1ad1 M73250 Payne & Sick, 1993 USP 5246852 1-3537
Table 2 (contd).
Name Acc No Reference Journal Coding
Cry1ad2 A27531 Payne & Sick, 1995 AUP 632335 1-3537
Cry1ae1 M65252 Lee & Aronson, 1991 J Bact 173 6635-6638 81-3623
Cry1af1 U82003 Kang et al., 1997 unpublished 172->2905
Cry1ag1 AF081248 Osman, 1998 unpublished
Cry1ba1 X06711 Brizzard & Whiteley, 1988 NAR 16 2723-2724 1-3684
Cry1ba2 X95704 Soetaert, 1996 unpublished 186-3869
Cry1bb1 L32020 Donovan et al., 1994 USP 5322687 67-3753
Cry1bc1 Z46442 Bishop et al., 1994 unpublished 141-3839
Cry1bd1 U70726 Kuo & Chak, 1999 unpublished 842-4534
Cry1be1 Payne et al., 1998 USP 5723758 1-3681
Cry1ca1 X07518 Honee et al., 1988 NAR 16 6240-6240 47-3613
Cry1ca2 X13620 Sanchis et al., 1989 Mol Micro 3 229-238 241->2711
Cry1ca3 M73251 Payne & Sick, 1993 USP 5246852 1-3570
Cry1ca4 A27642 Van Mellaert et al., 1990 EP 0400246 234-3800
Cry1ca5 X96682 Strizhov, 1996 unpublished 1->2286
Cry1cb1 M97880 Kalman et al., 1993 AEM 59 1131-1137 296-3823
Cry1da1 X54160 Hofte et al., 1990 NAR 18 5545-5545 264-3758
Cry1da2 I76415 Payne & Sick, 1997 USP 5691308 1-3495
Cry1db1 Z22511 Lambert, 1993 unpublished 241-3720
Cry1ea1 X53985 Visser et al., 1990 J Bact 172 6783-6788 130-3642
Cry1ea2 X56144 Bosse et al., 1990 NAR 18 7443-7443 1-3516
Cry1ea3 M73252 Payne & Sick, 1991 USP 5039523 1-3516
Cry1ea4 U94323 Barboza-Corona et al., 1998 WJMB 14 437-441 388-3900
Cry1ea5 A15535 Botterman et al., 1994 EP 0358557 54-3566
Cry1eb1 M73253 Payne & Sick, 1993 USP 5206166 1-3522
Cry1fa1 M63897 Chambers et al., 1991 J Bact 173 3966-3976 478-3999
Cry1fa2 M73254 Payne & Sick, 1993 USP 5188960 1-3525
Cry1fb1 Z22512 Lambert, 1993 unpublished 483-4004
Cry1fb2 AB012288 Masuda & Asano, 1998 unpublished 84-3587
Cry1fb3 AF062350 Song & Zhang, 1998 unpublished
Cry1fb4 I73895 Payne et al., 1997 USP 5686069 peptide seq
Cry1ga1 Z22510 Lambert, 1993 unpublished 67-3564
Cry1ga2 Y09326 Shevelev et al., 1997 Febs Lett 404 148-152 692-4210
Cry1gb1 U70725 Kuo & Chak, 1999 unpublished 532-4038
Cry1ha1 Z22513 Lambert, 1993 unpublished 530-4045
Table 2 (contd).
Name Acc No Reference Journal Coding
Cry1hb1 U35780 Koo et al., 1995 unpublished 728-4195
Cry1ia1 X62821 Tailor et al., 1992 Mol Micro 6 1211-1217 355-2511
Cry1ia2 M98544 Gleave et al., 1993 AEM 59 1683-1687 1-2160
Cry1ia3 L36338 Shin et al., 1995 AEM 61 2402-2407 279-2438
Cry1ia4 L49391 Kostichka et al., 1996 J Bact 178 2141-2144 61-2217
Cry1ia5 Y08920 Selvapandiyan, 1996 unpublished 524-2680
Cry1ia6 AF076953 Zhong et al., 1998 unpublished 1-2157
Cry1ib1 U07642 Shin et al., 1995 AEM 61 2402-2407 237-2393
Cry1ic1 AF056933 Osman et al., 1998 unpublished 1-2157
Cry1i-like I90732 Payne et al., 1998 See Table 3 peptide seq
Cry1ja1 L32019 Donovan et al., 1994 USP 5322687 99-3519
Cry1jb1 U31527 Von Tersch & Gonzalez, 1994 USP 5356623 177-3686
Cry1jc1 I90730 Payne et al., 1998 USP 5723758 peptide seq
Cry1ka1 U28801 Koo et al., 1995 FEMS 134 159-164 451-4098
Cry1-like I90729 Payne et al., 1998 See Table 3 peptide seq
Cry2aa1 M31738 Donovan et al., 1989 JBC 264 4740-4740 156-2054
Cry2aa2 M23723 Widner & Whiteley, 1989 J Bact 171 965-974 1840-3741
Cry2aa3 D86064 Sasaki et al., 1997 Curr Micro 35 1-8 2007-3911
Cry2aa4 AF047038 Misra et al., 1998 Unpublished 10-1908
Cry2aa5 AJ132464 Yu & Pang, 1999 Unpublished <1-1860
Cry2aa6 AJ132465 Yu & Pang 1999 Unpublished <1-1860
Cry2aa7 AJ132463 Yu & Pang, 1999 Unpublished <1->1611
Cry2ab1 M23724 Widner & Whiteley, 1989 J Bact 171 965-974 1-1899
Cry2ab2 X55416 Dankocsik et al., 1990 Mol Micro 4 2087-2094 874-2775
Cry2ac1 X57252 Wu et al., 1991 FEMS 81 31-36 2125-3990
Cry3aa1 M22472 Herrnstadt et al., 1987 Gene 57 37-46 25-1956
Cry3aa2 J02978 Sekar et al., 1987 PNAS 84 7036-7040 241-2175
Cry3aa3 Y00420 Hofte et al., 1987 NAR 15 7183-7183 566-2497
Cry3aa4 M30503 McPherson et al., 1988 Bio/technology 6 61-66 201-2135
Cry3aa5 M37207 Donovan et al., 1988 MGG 214 365-372 569-2503
Cry3aa6 U10985 Adams et al., 1994 Mol Micro 14 381-389 569-2503
Cry3ba1 X17123 Sick et al., 1990 NAR 18 1305-1305 25-1977
Cry3ba2 A07234 Peferoen et al., 1990 EP 0382990 342-2297
Cry3bb1 M89794 Donovan et al., 1992 AEM 58 3921-3927 202-2157
Cry3bb2 U31633 Donovan et al., 1995 USP 5378625 144-2099
Table 2 (contd).
Name Acc No Reference Journal Coding
Cry3bb3 I15475 Peferoen et al., 1995 USP 5466597 <1->1291
Cry3ca1 X59797 Lambert et al., 1992 Gene 110 131-132 232-2178
Cry4aa1 Y00423 Ward & Ellar, 1987 NAR 15 7195-7195 1-3540
Cry4aa2 D00248 Sen et al., 1988 ABC 52 873-878 393-3935
Cry4ba1 X07423 Chungjatpornchai et al., 1988 EJB 173 9-16 157-3564
Cry4ba2 X07082 Tungpradubkul et al., 1988 NAR 16 1637-1638 151-3558
Cry4ba3 M20242 Yamamoto et al., 1988 Gene 66 107-120 526-3933
Cry4ba4 D00247 Sen et al., 1988 ABC 52 873-878 461-3868
Cry5aa1 L07025 Sick et al., 1994 USP 5281530 1-4155
Cry5ab1 L07026 Narva et al., 1991 EP 0462721 1-3867
Cry5ac1 I34543 Payne et al., 1997 USP 5596071 1-3660
Cry5ba1 U19725 Payne et al., 1997 USP 5596071 1-3735
Cry6aa1 L07022 Narva et al., 1993 USP 5236843 1-1425
Cry6ba1 L07024 Narva et al., 1991 EP 0462721 1-1185
Cry7aa1 M64478 Lambert et al., 1992 AEM 58 2536-2542 184-3597
Cry7ab1 U04367 Payne & Fu, 1994 USP 5286486 1-3414
Cry7ab2 U04368 Payne & Fu, 1994 USP 5286486 1-3414
Cry8aa1 U04364 Foncerrada et al., 1992 EP 0498537 1-3471
Cry8ba1 U04365 Michaels et al., 1993 WO 93/15206 1-3507
Cry8ca1 U04366 Ogiwara et al., 1995 Curr Micro 30 227-235 1-3447
Cry9aa1 X58120 Smulevitch et al., 1991 FEBS 293 25-28 5807-9274
Cry9aa2 X58534 Gleave et al., 1992 JGM 138 55-62 385->3837
Cry9ba1 X75019 Shevelev et al., 1993 FEBS 336 79-82 26-3488
Cry9ca1 Z37527 Lambert et al., 1996 AEM 62 80-86 2096-5569
Cry9da1 D85560 Asano et al., 1997 AEM 63 1054-1057 47-3553
Cry9Da2 AF042733 Wasano & Ohba, 1998 Unpublished <1->1937
Cry9Ea1 AB011496 Midoh & Oyama, 1998 Unpublished 211-3660
Cry9 like AF093107 Wasano & Ohba, 1998 See Table 3 <1->1917
Cry10Aa1 M12662 Thorne et al., 1986 J Bact 166 801-811 941-2965
Cry10Aa2 E00614 Uorufuiirudo, 1996 JP 1986005098 940-2968
Cry11Aa1 M31737 Donovan et al., 1988 J Bact 170 4732-4738 41-1969
Cry11Aa2 M22860 Adams et al., 1989 J Bact 171 521-530 <1-235
Cry11Ba1 X86902 Delecluse, 1995 AEM 61 4230-4235 64-2238
Cry11Bb1 AF017416 Orduz et al., 1998 BBA 1388 267-272 97-2346
Cry12Aa1 L07027 Narva et al., 1991 EP 0462721 1->3771
Table 2 (contd).
Name Acc No Reference Journal Coding
Cry13Aa1 L07023 Narva et al., 1992 WO 92/19739 1-2409
Cry14Aa1 U13955 Narva et al., 1994 WO 94/16079 1-3558
Cry15Aa1 M76442 Brown & Whiteley, 1992 J Bact 174 549-557 1036-2055
Cry16Aa1 X94146 Barloy et al., 1996 J Bact 178 3099-3105 158-1996
Cry17Aa1 X99478 Barloy et al., 1998 Gene 211 293-299 12-1865
Cry18Aa1 X99049 Zhang et al., 1997 J Bact 179 4336-4341 1451-3571
Cry19Aa1 Y07603 Rosso & Delecluse, 1996 AEM 63 4449-4455 719-2662
Cry19Ba1 D88381 Hwang et al., 1998 SAB 21 179-184 626-2671
Cry20Aa1 U82518 Lee & Gill, 1997 AEM 63 4664-4670 60-2318
Cry21Aa1 I32932 Payne et al., 1996 USP 5589382 1-3501
Cry21Aa2 I66477 Feitelson, 1997 USP 5670365 1-3501
Cry22Aa1 I34547 Payne et al., 1997 USP 5596071 1-2169
Cry23Aa1 AF03048 Donovan & Slaney, 1998 WO 98/13498
Cry24Aa1 U88188 Kawalek & Gill, 1998 Unpublished 1-2022
Cry25Aa1 U88189 Kawalek & Gill, 1998 Unpublished 1-2028
Cyt1Aa1 X03182 Waalwijk et al., 1985 NAR 13 8207-8217 140-886
Cyt1Aa2 X04338 Ward & Ellar, 1986 JMB 191 1-11 509-1255
Cyt1Aa3 Y00135 Earp & Ellar, 1987 NAR 15 3619-3619 36-782
Cyt1Aa4 M35968 Galjart et al., 1987 Curr Micro 16 171-177 67-816
Cyt1Ab1 X98793 Thiery et al., 1997 AEM 63 468-473 28-777
Cyt1Ba1 U37196 Payne et al., 1995 USP 5436002 1-795
Cyt2Aa1 Z14147 Koni & Ellar, 1993 JMB 229 319-327 270-1046
Cyt2Ba1 U52043 Guerchicoff et al., 1997 AEM 63 2716-2721 287-655
Cyt2Ba2 AF020789 Guerchicoff et al., 1997 AEM 63 2716-2721 <1->469
Cyt2Ba3 AF022884 Guerchicoff et al., 1997 AEM 63 2716-2721 <1->469
Cyt2Ba4 AF022885 Guerchicoff et al., 1997 AEM 63 2716-2721 <1->469
Cyt2Ba5 AF022886 Guerchicoff et al., 1997 AEM 63 2716-2721 <1->471
Cyt2Ba6 AF034926 Guerchicoff et al., 1997 AEM 63 2716-2721 <1->472
Cyt2Bb1 U82519 Cheong & Gill, 1997 AEM 63 3254-3260 416-1204
spectra observed in Bt (González & Carlton, 1980; González et al.,
1981; González et al., 1982; Reddy et al., 1987; Jarrett & Stephenson,
1990). New Bt strains have been developed by conjugation that are
toxic to two insect orders.
2.1.6 Beta-exotoxin
Beta-exotoxin is associated with certain Bt subspecies (Btd, Btg,
Btte and Btt), and products made from these Bt subspecies may contain
the toxin (Cantwell et al., 1964; Mohd-Salleh et al., 1980). This
heat-stable nucleotide, which is composed of adenine, glucose and
allaric acid, inhibits RNA polymerase enzymes by acting competitively
with ATP (Faust, 1973; Farkas et al., 1977). Since RNA synthesis is a
vital process in all life, beta-exotoxin exerts its toxicity for
almost all forms of life tested including numerous insect species in
the orders Coleoptera, Diptera and Lepidoptera. The presence of
beta-exotoxin can be assayed using houseflies (Musca domestica) or
high-performance liquid chromatography (HPLC) techniques (Campbell et
al., 1987).
Bt containing beta-exotoxin is used for the control of houseflies
in some countries, but regulatory agencies currently prohibit the use
of beta-exotoxin for other purposes.
2.1.7 Other Bt metabolites
Commercial Bt products do not contain metabolites that are
considered hazardous to humans and the environment. However, Bt, like
other bacteria, may produce during the vegetative growth and
sporulation stages an assortment of antibiotics, enzymes, metabolites
and toxins that are biologically active and may have effects on both
target and non-target organisms (NTOs).
Using a non-quantitative (Lund & Granum, 1997) commercial Bc
enterotoxin immunoassay (Tecra), Damgaard (1995) reported that
vegetative cells grown from spores of commercial Bt products excreted
a diarrhoeal enterotoxin. Damgaard et al. (1996a) found by Vero cell
assay that Bt isolated from food was enterotoxigenic. None of these
investigations estimated the quantity or activity of enterotoxins
produced by the Bt strains. However, Shinagawa (1990) investigated a
number of Bc and Bt isolates with an immunological assay and concluded
that 43% of the Bt isolates had the same level of enterotoxins as
enterotoxic Bc. Tayabali & Seligy (1997) found that vegetative Bt
obtained from commercial products caused extensive damage to
cultivated insect cells.
At least three enterotoxic activities have been described in Bc
(Agata et al., 1995; Lund & Granum, 1997), and some Bc isolates are
known to produce an emetic toxin (Andersson et al., 1998). The emetic
toxin is primarily associated with the Bc H-1 (Kramer & Gilbert, 1992;
Nishikawa et al., 1996) serotype, and has not so far been associated
with Bt isolates.
Table 3. Bt-associated toxins or toxin-like proteins that have not been assigned a name or entered
into the nomenclature for the reasons given
Name Accession Journal Coding region Reason Reference
Cry1i-like I90732 USP 5723758 Peptide seq Insufficient sequence data Payne et al., 1998
Cry1-like I90729 USP 5723758 Peptide seq Insufficient sequence data Payne et al., 1998
Cry9-like AF093107 unpublished <1->1917 Insufficient sequence data Wasano & Ohba, 1998
40kda M76442 J Bact 174 549-557 45-971 No reported toxicity Brown & Whiteley, 1992
Cryc35 X92691 unpublished 1-981 No reported toxicity Juarez-Perez et al., 1995
Crytdk D86346 unpublished 177-2645 No reported toxicity Hashimoto, 1996
Cryc53 X98616 unpublished 1-1005 No reported toxicity Juarez-Perez et al., 1996
p21med X98794 AEM 63 468-473 1-552 No reported toxicity Thiery et al., 1997
ET34 AF038049 WO 98/13498 No reported toxicity Donovan & Slaney, 1998
Vip3a(a) L48811 PNAS 93 5389-5394 739-3105 Not a crystal protein Estruch et al., 1996
Vip3a(b) L48812 PNAS 93 5389-5394 118-2484 Not a crystal protein Estruch et al., 1996
Table 4. Bacillus thuringiensis holotype toxins
Name Old name Name Old name
Cry1Aa CryIA(a) Cry5Ac
Cry1Ab CryIA(b) Cry5Ba
Cry1Ac CryIA(c) Cry6Aa CryVIA
Cry1Ad CryIA(d) Cry6Ba CryVIB
Cry1Ae CryIA(e) Cry7Aa CryIIIC
Cry1Af Cry7Ab CryIIICb
Cry1Ag Cry8Aa CryIIIE
Cry1Ba CryIB Cry8Ba CryIIIG
Cry1Bb ET5 Cry8Ca CryIIIF
Cry1Bc PEG5 Cry9Aa CryIG
Cry1Bd CryE1 Cry9Ba CryIX
Cry1Be Cry9Ca CryIH
Cry1Ca CryIC Cry9Da
Cry1Cb CryIC(b) Cry9Ea
Cry1Da CryID Cry10Aa CryIVC
Cry1Db PrtB Cry11Aa CryIVD
Cry1Ea CryIE Cry11Ba Jeg80
Cry1Eb CryIE(b) Cry11Bb
Cry1Fa CryIF Cry12Aa CryVB
Cry1Fb PrtD Cry13Aa CryVC
Cry1Ga PrtA Cry14Aa CryVD
Cry1Gb CryH2 Cry15Aa 34kDa
Cry1Ha PrtC Cry16Aa cbm71
Cry1Hb Cry17Aa cbm72
Cry1Ia CryV Cry18Aa CryBP1
Cry1Ib CryV Cry19Aa Jeg65
Cry1Ic Cry19Ba
Cry1Ja ET4 Cry20Aa
Cry1Jb ET1 Cry21Aa
Cry1Jc Cry22Aa
Cry1Ka Cry23Aa
Cry2Aa CryIIA Cry24Aa Jeg72
Cry2Ab CryIIB Cry25Aa Jeg74
Cry2Ac CryIIC Cry26Aa
Cry3Aa CryIIIA Cry27Aa
Cry3Ba CryIIIB Cry28Aa
Cry3Bb CryIIIBb Cyt1Aa CytA
Cry3Ca CryIIID Cyt1Ab CytM
Cry4Aa CryIVA Cyt1Ba
Cry4Ba CryIVB Cyt2Aa CytB
Cry5Aa CryVA(a) Cyt2Ba "CytB"
Cry5Ab CryVA(b) Cyt2Bb
Alpha-toxin is a phospholipase C, which primarily affects the
cell membrane phospholipids (Heimpel, 1954; Bonnefoi & Béguin, 1959).
Gamma-toxin is toxic to sawflies (Tenthredinidae), but the mode of
action of this heat-labile toxin has not been determined (Heimpel,
1967).
The so called "water-soluble toxin" paralyses Lepidoptera
(Fast, 1971), and the "mouse factor exotoxin" is toxic to mice as
well as to Lepidoptera (Krieg, 1971). The modes of action of these
toxins have not been delineated.
A novel Bt vegetative insecticidal protein (Vip3A) has been
identified from the culture media of some Bt strains (Estruch et al.,
1996).
Several Bt and Bc enzymes have been described which may play a
role in non-target activity: phospholipase (Damgaard et al., 1996b),
sphingomyelinase (Gilmore et al., 1989), protease (Hotha & Banik,
1997), chitinase (Sampson & Gooday, 1998), and haemolysin (Baida &
Kuzmin, 1995).
2.2 Bioassays
2.2.1 Spore counts
Bacterial spore counts do not necessarily reflect the
insecticidal activity of a Bt strain or Bt product because the number
and amount of ICPs produced per bacterial cell can vary.
2.2.2 International bioassay for ICPs
The final formulation of each Bt product is bioassayed against an
accepted international standard using a specific test insect (Dulmage
et al., 1981; de Barjac & Larget-Thiery, 1984). Its potency is defined
in ITU/mg product. The standardization allows comparison of different
formulations in the laboratory. Currently, the larvicidal activity is
expressed in terms of lethal doses (LD50) or lethal concentrations
(e.g., LC50, LC90) according to the bioassay method used. For
example, when susceptible mosquito larvae are exposed to Bti ICP, they
have an LC50 of approximately 10 ng/ml water. A Bti whole culture
gives an LC50 of approximately 103 cells/ml for susceptible mosquito
larvae while a 109 cells/ml culture does not affect any laboratory
mammals exposed by various routes.
3. MODE OF ACTION ON TARGET INSECTS
3.1 Bioactivity of field isolates
The mode of action of Bt has been reviewed by Schnepf et al.
(1998) and can be summarized in the following stages: 1) ingestion of
sporulated Bt and ICP by an insect larva; 2) solubilization of the
crystalline ICP in the midgut; 3) activation of the ICP by proteases;
4) binding of the activated ICP to specific receptors in the midgut
cell membrane; 5) insertion of the toxin in the cell membrane and
formation of pores and channels in the gut cell membrane, followed by
destruction of the epithelial cells (Cooksey, 1971; Norris 1971; Fast,
1981; Huber & Lüthy, 1981; Lüthy & Ebersold, 1981; Smedley & Ellar,
1996); and 6) subsequent Bt spore germination and septicaemia may
enhance mortality (Fig. 1).
The specific bioactivity of Bt is dominated by the ICPs that are
encoded by the cry genes and are active against susceptible species
in the insect orders Coleoptera, Diptera and Lepidoptera.
Specific Bt activities against other insect orders (Hymenoptera,
Homoptera, Dictyoptera, Mallophaga) and to nematodes
(Strongylida, Tylenchida), mites (Acari), flatworms (Digenea)
and protozoa (Diplomonadida) have been described (Feitelson, 1993;
Zukowski, 1995). The ICP must be ingested to be effective against the
target (Visser et al., 1993).
3.2 Mechanism of action of Bt formulations
The ICP-spore complexes of Bt are ingested by susceptible insect
larvae. In the midgut the parasporal crystalline ICP is dissociated to
the protoxin form, and the protoxin is then activated to a holotoxin
by gut proteases (Warren et al., 1984; Jaquet et al., 1987; Aronson et
al., 1991; Honée & Visser, 1993). Shortly afterwards, the gut becomes
paralysed and the larva ceases to feed.
The ICP structure and function have been reviewed in detail by
Schnepf et al. (1998). Binding of the ICP to putative receptors is a
major determinant of ICP specificity and the formation of pores in the
midgut epithelial cells is a major mechanism of toxicity (Van
Frankenhuyzen, 1993).
The active toxin consists of three distinct domains (Höfte &
Whiteley, 1989; Li et al., 1991; Grochulski et al., 1995). The three
domains interact in a complex manner, but experimental data suggest
that the C-terminal and middle domains of the toxin are involved in
epithelial cell receptor binding and structural functions, while the
N-terminal domain is primarily involved in ion channel and pore
formation (Huber et al., 1981; Schnepf et al., 1998; Dean et al.,
1996).
Binding to specific receptors has been demonstrated to be closely
related to the insecticidal spectrum of the ICPs (Denolf et al.,
1997). Van Rie et al. (1989) found the affinity of these toxins
similar for the tobacco budworm (Heliothis virescens) and the tomato
hornworm (Manduca sexta) brush border membrane vesicles, but the
number of binding sites differed and reflected varied bioactivity.
However, the toxin affinity for binding sites does not appear constant
for all insects.
Pore or ion channel formation occurs after the binding to the
receptor and insertion of the N-terminal domain into the membrane,
whereby the regulation of the trans-membrane electric potential is
disturbed. This can result in colloid-osmotic lysis of the cells,
which is the main cytolytic mechanism that is common to all ICPs
(Knowles & Ellar, 1987; Slatin et al., 1990; Schwartz et al., 1991;
Schnepf et al., 1998). When the midgut epithelium of the larva is
damaged, the haemolymph and gut contents can mix. This results in
favourable conditions for the Bt spores to germinate. The resulting
vegetative cells of Bt and the pre-existing microorganisms in the gut
proliferate in the haemocoel causing septicaemia, and may thus
contribute to the mortality of the insect larva.
3.3 Resistance of insect populations
A number of insect populations of several different species with
different levels of resistance to Bt have been obtained by laboratory
selection experiments during the last 15 years (Schnepf et al., 1998).
The species include Plodia interpunctella, Cadra cautella,
Leptinotarsa decemlineata, Chrysomela scripta, Tricholplusia ni,
Spodoptera littoralis, Spodoptera exigua, Heliothis virescens,
Ostrinia nubilalis and Culex quinquefasciatus (Schnepf et al.,
1998) and resistance is shown to either Btk, Bti, Btte or other Bt
subspecies.
During the last few years populations of the diamondback moth,
Plutella xylostella, resistant to Btk and Bta have been found in
heavily treated areas in numerous geographically isolated regions in
the world, including Hawaii, Phillippines, Indonesia, Malaysia,
Central America and some USA states (Schnepf et al., 1998). It is
clear that this widespread appearance of resistance to Bt presents a
cautionary tale for the way of using Bt and Bt toxin genes in pest
management. Schnepf et al. (1998) have reviewed resistance management
of Bt.
4. NATURAL AND TREATED HABITATS
The Bt subspecies represents a group of organisms that occur
naturally and can be added to an ecosystem to achieve insect control
(Andrews et al., 1987; Stahly et al., 1991). In this monograph, a
natural habitat is considered to be one where Bt can be isolated when
there has been no previous history of application of the organism to
that ecosystem, whereas a treated habitat is one where Bt can be
isolated after a previous history of application of the organism for
insect control.
Insecticides formulated with Bt are being manufactured and used
worldwide. These commercial Bt products may be applied as an
insecticide to foliage, soil, water environments and food storage
facilities. After application of Bt to an ecosystem, the organism may
persist as a component of the natural microflora.
4.1 Natural occurrence of Bt
Members of the Bacillus cereus group can be found in most
ecological niches. Hansen et al. (1996) reviewed the occurrence of Bt
in the environment. Although the early Bt isolates were pathogenic for
insects, it is now apparent that several Bt isolates have no known
target (Ohba & Aizawa, 1986; Ohba et al., 1988; Hansen et al., 1996,
1998; Damgaard et al., 1997b). This lack of insecticidal activity may
be attributed to the loss of ability to produce ICPs (Gordon, 1977),
which may be due to a mutation in the ICP gene that could prevent
expression (Klier & Lecadet, 1976; Stahly et al., 1978; Dean, 1984) or
to the loss of ICP encoding sequences. Finally, the lack of known
activity of a Bt crystalline toxin might simply be explained by a
failure to test against the actual target organism. The list of Bt
targets is still increasing. Although our knowledge of the activity of
Bt populations in the environment is limited, a certain level of
turn-over and vegetative growth must occur, as annual and seasonal
variations in numbers and subspecies diversity of Bt populations have
been observed (Damgaard et al., 1997b; Kim et al., 1998).
4.1.1 Bt in insect hosts
Numerous Bt subspecies have been isolated from dead or dying
insect larvae and in most cases the isolate has toxic activity to the
insect from which it was isolated (Goldberg & Margalit, 1977; de
Barjac, 1981b; Hansen et al., 1996). These organisms have a narrow
host range in the orders Coleoptera, Diptera and Lepidoptera and
can proliferate within the bodies of their host insects. When the
infected insect larva dies, the dead insect carcass usually contains
relatively large quantities of spores and crystals that may be
released into the environment (Prasertphon et al., 1973; Grassi &
Deseö, 1984; Aly, 1985; Aly et al., 1985). Growth of Bt in non-target
organisms has also been described. Eilenberg et al. (in press) found
that Bt multiplication had occurred in non-target insects, which were
also infected by insect pathogenic fungi.
Akiba (1986) reported recycling of naturally occurring Bt in
insect cadavers when competitive microorganisms were at a low density.
Outbreaks of Bt in susceptible insect populations occur relatively
infrequently; most outbreaks have been limited to situations where the
insect density is relatively high, providing better opportunity for
establishing the disease within the insect population (Lynch et al.,
1976; Burges & Hurst, 1977; Vaňková & Purrini, 1979; Margalit & Dean,
1985).
4.1.2 Bt in soil
The spores of Bt persist in soil, and vegetative growth occurs
when nutrients are available (DeLucca et al., 1981; Akiba, 1986; Ohba
& Aizawa, 1986; Travers et al., 1987; Martin & Travers, 1989).
DeLucca et al. (1981) found that Bt represented between 0.5% and
0.005% of all Bacillus species isolated from soil samples in the
USA. Martin & Travers (1989) recovered Bt from soils globally. Meadows
(1993) isolated Bt from 785 of 1115 soil samples, and the percentage
of samples that contained Bt ranged from 56% in New Zealand to 94% in
samples from Asia and central and southern Africa. Ohba & Aizawa
(1986) isolated Bt from 136 out of 189 soil samples in Japan.
4.1.3 Bt on plant surfaces
Bt has been found extensively in the phylloplane. Numerous Bt
subspecies have been recovered from coniferous trees, deciduous trees
and vegetables, as well as from other herbs (Smith & Couche, 1991;
Damgaard et al., 1997b). The Bt isolates have demonstrated a broad
diversity both with specific activities to insects from the orders
Coleoptera and Lepidoptera and with unknown activities (Smith &
Couche, 1991; Damgaard et al., 1997b; Hansen et al., 1998). The
bacterium has also been isolated from stored grain products (Meadows
et al., 1992).
4.2 Treated habitats
Treated habitats are the locations where Bt insecticides (usually
a mixture of spores and crystals) have been applied.
In Canada, Meadows (1993) estimated that approximately 1015
viable Btk spores per ha were released in a typical spray operation to
control spruce budworm (Choristoneura fumiferana).
4.3 Environmental fate, distribution and movement
Bt, like other members of the genus Bacillus, has the ability
to form endospores that are resistant to inactivation by heat and
desiccation and that persist in the environment under adverse
conditions (Stahly et al., 1991). When considering the degradation of
Bt in the environment, it is important to distinguish between changes
in the numbers of viable spores and changes in biocidal activity. The
survival and activity in the environment has been reviewed by Hansen
et al. (1996).
The distribution and environmental transport of applied Bt
formulations are influenced by the type of application and various
environmental factors (Bulla et al., 1985; Andrews et al., 1987). Bt
formulations are used in agriculture and forestry against coleopteran
and lepidopteran pests and are usually directed towards the surface of
plants, while the Bt formulations for control of dipteran pests
(mosquitos and blackflies) are applied to their aquatic, larval
habitats. Many Bt insecticides exhibit poor stability under field
conditions, and so frequent reapplication is required (Griego &
Spence, 1978; Sorenson & Falcon, 1980; Beegle et al., 1981).
4.3.1 Distribution and fate of Bt in terrestrial habitats
4.3.1.1 Fate of Bt and ICP on plant surfaces
Solar radiation appears to be the environmental factor most
damaging to the stability of Bt ICP (Pinnock et al., 1974; Pinnock et
al., 1977; Griego & Spence, 1978; Pusztai et al., 1991).
Griego & Spence (1978) demonstrated that Bt spores are
inactivated rapidly when exposed to UV radiation, while Pusztai et al.
(1991) demonstrated that the tryptophan residues of the Bt protoxin
are damaged by solar radiation in the 300-380 nm range.
The combined effect of sunlight, leaf temperature and vapour
pressure deficit appeared to contribute more to the reduction of
bioactivity than any other single factor (Leong et al., 1980). Residue
bioactivity may be detected up to 2 weeks after treatment with
formulations containing UV protectants (Hostetter et al., 1975). Other
studies on the effect of environmental exposure to Bt spores revealed
that spore survival can be affected by the surface to which the
material is applied.
Pinnock et al. (1974) reported that the half-life of Bt spores on
leaves of California live oak (Quercus agrifolia) was 3.9 days, as
compared to a half-life of 0.63 days when applied to leaves of western
redbud (Cercis occidentalis).
Ignoffo (1992) summarized data for the reduction of spore
viability and ICP activity on leaves of various plants in sunlight: Bt
spore viability was reduced 80% in one day on red cedar leaves and 8%
on soy bean leaves, while the ICP activity declined by 20% on red
cedar leaves but 65% on soy bean leaves.
Dent (1993) reported that Bt formulations on foliage frequently
have half-lives of up to 10 days. However, unformulated Bt may have a
half-life of only a few hours. Pedersen et al. (1995) found that the
initial spore half-life was 16 h during the first week after spraying
cabbage with unformulated Btk.
There is also evidence that plant chemicals can inactivate Bt or
influence infectivity. Lüthy (1986) demonstrated that extracts
prepared from cotton leaves could inactivate ICPs.
Commercially applied Bt may persist at low levels for
considerable periods of time. Reardon & Haissig (1983) reported that
Btk was still present on balsam fir (Abies balsamea) one year after
applications to control spruce budworm. The proliferation of spores
through infection of susceptible insects should not be discounted as a
source of low levels of Bt in treated areas. Several studies have
demonstrated that Bt is able to grow and sporulate in insect cadavers
(Meadows, 1993). From dead Egyptian cotton leafworm (Spodoptera
littoralis), Jarrett & Stephenson (1990) isolated between 5.0 × 105
and 9.2 × 107 spores per larva.
Bt may be lost to the soil by overspray during application or by
the action of rain on plant surfaces. Further losses arise from in
situ degradation by environmental factors, such as ultraviolet (UV)
radiation and microbial activity (Griego & Spence, 1978; Sorenson &
Falcon, 1980; Beegle et al., 1981; West et al., 1984a,b). Pedersen et
al. (1995) found that Bt was dispersed by rain splash from the soil to
the lower leaves of cabbage.
4.3.1.2 Fate of Bt in soil
Petras & Casida (1985) reported that Bt spore counts in soil
declined by a factor of ten in the first 2 weeks after application and
then remained constant for 8 months. The response was similar in
spores from commercial and laboratory cultures. In contrast,
vegetative cells introduced into the soil persisted for only a short
time. Soil pH had little effect on their survival. Spore persistence
for more than 2 weeks apparently resulted from the inability of the
spores to germinate in the soil.
Pedersen et al. (1995) sprayed unformulated Btk (1.2 5 104 cfu
per g soil, spontaneous rifampicin-resistant mutant) on soil in 1993,
and 2.3 × 103 cfu per g soil remained after 336 days. The field was
left undisturbed, and 5´ years later spots with 1.5 × 103 Btk per g
soil were found (Hansen & Hendriksen, 1999), but spots with very low
Btk numbers were also recorded. These data indicate that the Btk had
multiplied.
West et al. (1984a,b) reported that vegetative cells in soil
disappeared at a rapid, exponential rate, whereas parasporal crystals
disappeared at a slower, non-exponential rate, and spore numbers
remained unaltered through 91 days of incubation at 25°C, with no
detectable germination. The proteinaceous crystalline protoxin of Bt
has been shown to be degraded by soil microorganisms at an exponential
rate with a half-life of about 3-6 days.
Saleh et al. (1970) reported that Bt spores could remain viable
for several months in the soil and germinate when soil conditions
favoured bacterial growth.
Bt spores do not appear to germinate readily in most soils and
the crystalline protoxins are metabolized by other microorganisms.
West et al. (1984a) reported that Bta in soil showed an exponential
loss of insecticidal activity. The rate of loss was greater in
non-sterile soil than in autoclaved soil. There was an initial rapid
decrease, which stabilized at approximately 10% of the original
inoculum level after 250 days incubation, until the cessation of
sampling after two years. No loss of insecticidal activity was
observed in autoclaved soil, which suggests that soil microorganisms
were responsible for the loss of insecticidal activity in the natural,
non-sterilized soil.
Several studies determined that Bt did not grow under most
natural soil conditions (West et al., 1984a,b; Akiba, 1986). The data
suggested that this was attributable to a failure of Bt spores to
germinate in soil under these conditions. The spore is the only state
in which Bt persists in natural soils.
An environmental fate study demonstrated no significant spore
accumulation in either the organic or the mineral layers of soil over
an 11-month period when Bt was applied aerially at 100 times the
concentration used for operational programmes (Bernier et al., 1990).
Studies have indicated that Bt is relatively immobile in soil.
Martin & Reichelderfer (1989) found no vertical movement beyond a 6-cm
deep zone in soil and less than 10 m lateral movement, even along
drainage courses.
Akiba (1991) reported a one-month irrigation study simulating the
summer rainy season in Japan. There was no translocation of Bt below a
depth of 10 cm. In soils receiving 45 cm simulated rainfall, Bt was
detected to a depth of 3-6 cm. In tests using soil columns, Bt did not
pass through a column of volcanic ash soil but a few spores were
detected in flow-through water from an alluvial sand column. Results
suggested that the major factor causing a decrease in the level of Bt
was not a physical dilution due to the rainwater, but possibly an
affinity of the spores for the soil particles.
Venkateswerlu & Stotsky (1992) reported that adsorption and
binding of Bt toxin proteins to soil particles were greater on
montmorillonite than on kaolinite clays. Maximum adsorption occurred
within 30 min, and adsorption was not significantly affected by
temperature between 7°C and 50°C.
4.3.2 Distribution and fate of Bt in aquatic habitats
Bti is often applied directly to water for the control of
mosquitos and blackflies. Rapid sedimentation in all but the fastest
flowing streams is regarded as an important limitation on the efficacy
of such applications.
Sheeran & Fisher (1992) demonstrated that the sedimentation of
Bti is facilitated by adsorption onto particulate material.
Ohana et al. (1987) found that spores may persist for at least
22 days in sediments, and the spores may be mobilized with such
sediments during floods.
Btk has been reported to survive in fresh water and in seawater
for more than 70 and 40 days, respectively, at 20°C (Menon & De
Mestral, 1985). A higher percentage of Btk was found to survive for
extended periods in lake water than in tap and distilled water,
presumably due to the presence of more nutrients in lake water. Bt has
not been isolated from any drinking-water supplies.
Spores of Bti remained viable for shorter periods when suspended
in moving water than when in static bottles, indicating that static
laboratory trials may overestimate the longevity of these spores in
the environment (Yousten et al., 1992).
Carcases of mosquito larvae killed by Bti have been shown to
allow for the complete growth cycle (germination, vegetative growth
and sporulation), thus becoming toxic themselves to scavenging yellow
fever mosquito (Aedes aegypti) larvae (Khawaled et al., 1990).
Contact of Bti with mud can result in an immediate disappearance
of larvicidal activity, but it has little influence on spore viability
(Ohana et al., 1987). The cessation of toxicity was found to be caused
by bacterial adsorption to soil particles, but the inactivation could
be reversed by washing the mud away.
Special Bti formulations have been developed to prolong residence
time of Bt at the surface or in the water column, where target insects
feed.
Manasherob et al. (1998) found germination, growth and
sporulation of Bti in excreted food vacuoles of a protozoan.
4.3.3 Transport of Bt by non-target organisms
In a field trial where Btk was sprayed on cabbage and soil,
Pedersen et al. (1995) found that the Btk could be transported by
non-target insects. Up to 103 cfu per g were found on surface-active
insects, and carabid beetles carrying Btk were found up to 135 m from
the Btk-treated area.
In a study of interactions between Bti and fathead minnows
(Pimephales promelas), ingestion of Bt resulted in a high number of
recoverable spores in the gastrointestinal tract and faeces (Snarski,
1990). Bti spore counts decreased rapidly after test fish were
transferred to clean water, but spores were detected in low numbers in
faeces for over 2 weeks. The data indicated that minnows could
disperse Bt spores in the freshwater environment.
Meadows (1993) reported that, after the application of Bt on
land, it may be dispersed by birds and mammals feeding on infected
target insects. Some Bt-infected insect larvae may contain 6.6 × 108
to 4.2 × 109 spores per gram dry mass (Burges & Hurst 1977).
5. COMMERCIAL PRODUCTION
5.1 History of Bt and its commercial applications
5.1.1 Production levels
Conventional Bt products, which utilize naturally occurring or
modified Bt strains, account for approximately 90% of the world MPCA
market (Bernhard & Utz, 1993). Current annual production of Bt has
been estimated at 3000 or more tonnes in developed countries. In
China, up to 10 000 tons are produced annually (personal communication
by Guan Xiong, Fujian Agricultural, University, 1997).
5.1.2 Production processes, formulations and quality standards
Bt products are produced using fermentation technology (Bernhard
& Utz, 1993). Most commercial products contain ICP and viable Bt
spores, but the spores are inactivated in some Bti products. During
commercial-scale production of Bt products, there is little loss of
bioactive components to the environment. The type of loss incurred is
a function of the recovery method involved. No significant amount of
bioactive component is lost from fermenter harvests if filtration is
used to separate the insoluble solids (active ingredients) from the
soluble liquid (inert) fraction of the harvest liquor, as shown by
complete lack of bioactivity in the resulting liquid fraction. The
liquid waste fractions may contain a low concentration of insoluble
active component, but this is typically inactivated by processing in
on-site waste treatment facilities. Although it is not a physical
loss, measurable bioactivity is diminished if the recovered active
material is processed through a dryer, due to the exposure of the
bioactive components to the high temperatures required for drying.
Guidelines for the handling of microorganisms during manufacture have
been reviewed by Frommer et al. (1989).
Commercial Bt formulations include wettable powders, suspension
concentrates, water dispersible granules, oil miscible suspensions,
capsule suspensions and granules (Tomlin, 1997).
Quality standards for Bt fermentation products have been accepted
by IUPAC (Quinlan, 1990). These standards include limits on the
concentration of microbial contaminants and metabolites (Table 5).
In most cases strains of Bt that produce beta-exotoxins are not
approved for commercial application, although some commercial use has
been approved for control of certain fly species that are not
susceptible to ICPs (Carlberg et al., 1985).
Table 5. Maximum allowable levels of microbial contamination in
bacterial insecticides (IUPAC Recommendation; Quinlan, 1990)
Types of microorganisms Maximum concentrations
Viable mesophiles <1 × 105/g
Viable yeasts and moulds <100/g
Coliforms <10/g
Staphylococcus aureus <1/g
Salmonella <1/10g
Lancefield Group D Streptococci <1 × 104/g
5.1.3 General patterns of use
Commercial applications of Bt have been directed mainly against
lepidopteran pests of agricultural and forest crops; however, in
recent years strains active against coleopteran pests have also been
marketed (Table 6).
Strains of Bti active against dipteran vectors of parasitic
disease organisms have been used in public health programmes.
5.1.3.1 Applications in agriculture and forestry
Commercial use of Bt on agricultural and forest crops dates back
nearly 30 years, when it became available in France. Use of Bt has
increased greatly in recent years and the number of companies with a
commercial interest in Bt products has increased from four in 1980 to
at least 18 (Van Frankenhuyzen, 1993). Several commercial Bt products
with Bta, Btk or Btte have been applied to crops using conventional
spraying technology (Table 6). Various formulations have been used on
major crops such as cotton, maize, soybeans, potatoes, tomatoes,
various crop trees and stored grains. Formulations have ranged from
ultralow-volume oil to high-volume, wettable powder and aqueous
suspensions. In the main, naturally occurring Bt strains have been
used, but transgenic microorganisms expressing Bt toxins have been
developed by conjugation and by genetic manipulation, and in some
cases, these have reached the commercial market. These modified
organisms have been developed in order to increase host range, prolong
field activity or improve delivery of toxins to target organisms. For
example, the coleopteran-active cryIIIA gene has been transferred to
a lepidopteran-active Btk (Carlton et al., 1990). A plasmid bearing an
ICP gene has been transferred from Bt to a non-pathogenic
leaf-colonizing isolate of Pseudomonas fluorescens; fixation of the
transgenic cells produces ICP contained within a membrane which
prolongs persistence (Gelernter, 1990). The gene expressing cryIA(c)
ICP has been inserted in Clavibacter xyli subspecies cynodontis, a
bacterium that colonizes plant vascular systems. This has been shown
to deliver the ICP effectively to European corn borer (Ostrinia
nubilalis) feeding within plant stems (Beach, 1990). Improvements in
performance arising from such modifications are such that transgenic
organisms and their products are likely to be used much more widely in
the future.
5.1.3.2 Applications in vector control
Bti has been used to control both mosquitos and blackflies in
large-scale programmes (Lacey et al., 1982; Chilcott et al., 1983;
Car, 1984; Car & de Moor, 1984; Cibulsky & Fusco, 1987; Becker &
Margalit, 1993; Bernhard & Utz, 1993). For example, in Germany 23
tonnes of Bti wettable powder and 19 000 litres of liquid concentrate
were used to control mosquitos (Anopheles and Culex species)
between 1981 and 1991 in the Upper Rhine Valley (Becker & Margalit,
1993). In China, approximately 10 tonnes of Bti have been used in
recent years to control the malarial vector, Anopheles sinensis.
The Onchocerciasis Control Programme of West Africa used more
than five million litres of Bti from 1982 to 1997 to control
blackflies (Simulium damnosum), the vector of the onchocerciasis
filarial worm (Onchocerca volvulus), on the Upper Volta River
System. The Programme was initially based solely on the control of the
vector, Simulium damnosum sensu lato, by spraying the insecticide
at breeding sites on river systems, where larval stages develop. At
the peak of larvicidal activities about 50 000 km of rivers were
treated in an area of over one million km2. The purpose was to
interrupt the transmission of the parasite Onchocerca volvulus. The
interruption of the cycle is achieved by destroying larval stages
through aerial application of insecticides to breeding sites.
Insecticide application was undertaken weekly (Moulinier et al.,
1995). In order to assess the environmental impact of such treatments
a network of sampling stations throughout the programme area were
established.
Formulations of Bti range from wettable powder and fluid
concentrates applied via conventional spray equipment from ground and
air to slow-release briquet and tablet formulations. Examples of
commercial Bti products are listed in Table 6.
Table 6. Examples of commercial Bt products used against agricultural, forestry and public health pests
(Tomlin, 1997; see also the Internet site http://www.sipweb.org/bacteria.htm)
Bt sub-species Commercial products Producer
Bt (not defined) Rijin Scientific & Technological Development
Bt (not defined) Bitayon Jewin-Joffe Industry Ltd
Bt (not defined) Delfin, Thuricide SDS Biotech KK
Btk Bactospeine, Biobit, Dipel, Foray Abbott (USA)
Bollgard Ecogen/Crop Care
Bactucide Caffaro
Baturad Cequisa
Condor, Crymax, Cutlass, Ecogen
Foil, Jackpot, Lepinox,
Rapax, Raven
Jackpot, Lepinox, Rapax Intrachem
Cordalene Agrichem
Larvo Troy
Costar, Delfin, Design, Novartis/Thermo Trilogy Co
Javelin, Steward, Thuricide,
Vault
Ecotech Bio, Ecotech Pro Ecogen/Roussel-Uclaf
Halt Wockhardt
Bta Xentari, Florbac Abbott
Certan Novartis
Btte Novodor Abbott
Bti Bactimos, Gnatrol, Vectobac Abbott
Acrobe Cyanamid
JieJueLing, MieJueLing Huazhong Agricultural University
Teknar Novartis/ThermoTrilogy Co
Bt Ybt-1520 Mianfeng pesticide Huazhong Agricultural University
Bt chinesensis Shuangdo preparation Huazhong Agricultural University
Btg Spicturin Tuticorin Alkali Chemicals and
Fertilisers Ltd
6. EFFECTS ON ANIMALS
6.1 Mammals
Microbial pest control agents (MPCA) can, in principle, cause
harmful effects via toxicity, inflammation, or a combination of these
effects. The presence of bacteria in a specimen derived from tissues
does not necessarily mean infection. Colonization refers to the
multiplication of MPCA either on the surface or within an animal/human
organism without causing any tissue damage. Persistence refers to
the ability to recover the inoculum of the MPCA over time. Persistence
and transient disturbances of the normal microbial flora are to be
expected after exposure of experimental animals to MPCA, since
clearance of the inoculum is not instantaneous. Persistence may not be
equated with infection (Siegel & Shadduck, 1990). Infection by a
MPCA means that there is evidence of the establishment and
proliferation of the MPCA in tissues, coupled with tissue damage.
Evidence of multiplication includes a measurable increase in the total
amount of MPCA, recovery of vegetative stages when spores were
administered, and failure of the inoculum to clear. It cannot be
determined solely on the basis of lesions since injection of foreign
material can elicit an inflammatory process (Siegel et al., 1987).
A classification of MPCA toxicity and infectivity has been
proposed, in which MPCA is classified as toxic if an oral dose
< 106 cfu per mouse causes mortality or clinical or pathological
changes (Burges, 1980). However, any classification is very difficult
because of the complexicity of the issue when dealing with living
organisms (Ignoffo, 1973; Shadduck, 1983).
Older reports do not discriminate between different strains of Bt
but modern molecular techniques have proven that variability exists
within strains with the same serotype (Helgason et al., 1998; Hansen &
Hendriksen, 1997a,b).
Mammalian toxicity studies on Bt-containing pesticides
demonstrate that the tested isolates are not toxic or pathogenic
(McClintock et al., 1995), as they occur in the products. Toxicity
studies submitted to the US Environmental Protection Agency to support
registration of Bt subspecies, and reviewed by McClintock et al.
(1995), failed to show any significant adverse effects on body weight
gain, clinical observations or upon necropsy.
Infectivity/pathogenicity studies have shown that the intact rodent
system responds as expected to eliminate Bt gradually from the body
after oral, pulmonary or intravenous challenge. However, clearance of
Bti and Btk is not instantaneous. An intact immune system is not a
prerequisite for clearance of Bti and Btk.
6.1.1 Oral exposure
In studies conducted with a single oral dose of laboratory grown
Bt and commercial Bt formulations, there was no mortality associated
with ingestion of Bti or Btk in mice and rats (Fisher & Rosner, 1959;
de Barjac et al., 1980; Shadduck, 1980; Siegel et al., 1987)
(Table 7).
Additionally, in data summarized by McClintock et al. (1995), no
toxicity or infectivity was observed following oral administration of
various Bt subspecies at doses of up to 4.7 × 1011 cfu/kg in rats.
In a study involving repeated oral exposure of mice and rats for
21 days with laboratory grown Bti, there was no mortality associated
with ingestion of Bti and normal weight gain was observed in all
treated rodents (de Barjac et al., 1980) (Table 8).
Hadley et al. (1987) conducted a study in which sheep were
repeatedly treated with two commercial Btk formulations for 60 days.
The only clinical sign was loose stools in sheep exposed to one Btk
formulation. There was also microscopic evidence of moderate to marked
lymphoid hyperplasia of the Peyer's patches in the caecum and colon of
two out of six sheep treated with one Btk formulation and in one out
of six sheep treated with the other Btk formulation. The authors did
not consider these findings clinically significant.
Other multiple dose studies with Bt were summarized by McClintock
et al. (1995). In rats, no toxicity or infectivity was associated with
dietary exposure to Bti (4 g/kg per day ) for 3 months. Administration
of 1.3 × 109 Btk spores/kg per day to rats by oral gavage was not
toxic or infectious. McClintock et al. (1995) also reported the
results of a 2-year study in which a commercial Btk preparation was
fed to rats at 8400 mg/kg per day in the diet. Despite this excessive
dose, the only effect observed was a decrease in body weight of
females during weeks 10-104 of the study.
6.1.2 Inhalation exposure
These tests primarily address the potential infectivity of a
MPCA. Inhalation is a likely route by which humans and animals may be
exposed to Bt during application.
De Barjac et al. (1980) exposed 10 female Swiss mice for 12 min
to 2 × 108 Bti spores (48-h laboratory grown whole culture). The mice
were monitored for clinical signs for 15 days, and then killed. The
lungs were removed aseptically and cultured for bacteria, but no Bti
was recovered.
Siegel et al. (1987) exposed 27 female Sprague-Dawley rats to
2 × 106 spores of a commercial Bti formulation for 30 min. Rats were
serially killed over a 27-day period and the lungs were cultured.
Table 7. Acute toxicity (single oral exposure) of Bt in experimental animals
Subspecies Material tested Test animal Dosea Mortalityb Reference
tested
Btk Washed cells, 24-h culturec Rat, female, Sprague-Dawley 1.4 × 107cfu 0/6 Shadduck, 1980
Btk Commercial product Ratd 2 × 1011cfu 0/10 Fisher & Rosner, 1959
Bti 48-h culturec Mouse, female, Swiss 1.7 × 108cfu 0/20 de Barjac et al., 1980
Bti 48-h culturec Rat, female, Wistar 3.4 × 107cfu 0/10 de Barjac et al., 1980
Bti Washed cellsc, 24-h culture Rat, female, Sprague-Dawley 6.9 × 107cfu 0/6 Shadduck, 1980
Bti Washed commercial product Rat, female, Sprague-Dawley 4 × 107cfu 0/10 Siegel et al., 1987
a All doses given are per animal
b Number dead/number treated
c Laboratory grown culture
d Breed and sex unknown
Table 8. Repeated dose (oral exposure) toxicity of Bt in mice, rats and sheep
Subspecies Material tested Test animal Dose Exposure Mortalitya Reference
tested time
Btk Commercial product Sheep, male, Rambouillet/Merino 1 × 1012cfu 5 months 0/6 Hadley et al., 1987
Btk Commercial product Sheep, male, Rambouillet/Merino 1 × 1012cfu 5 months 0/6 Hadley et al., 1987
Bti 48-h cultureb Mouse, female, Swiss 4.7 × 1010cfu 21 days 0/20 de Barjac et al., 1980
Bti 48-h cultureb Rat, female, Wistar 1.2 × 1011cfu 21 days 0/10 de Barjac et al., 1980
a Number dead/number exposed
b Laboratory grown culture
Recovery of Bti declined from 5.92 × 103 cfu/g lung tissue at 3 h
after exposure to none detected at 7 days after exposure. No gross
lung lesions were observed.
Fisher & Rosner (1959) exposed 10 mice to 3 × 1010 spores of a
commercial Btk product 4 times in a 6-day period. The Btk-treated mice
exhibited no clinical signs during the treatment period and no gross
pathological changes at necropsy.
6.1.3 Dermal exposure
This test is similar to the dermal exposure tests used in
chemical toxicology. Bt does not have any external contact toxicity
due to its mode of action, as shown in the following studies.
De Barjac et al. (1980) applied 5.1 × 107 cfu Bti of a 48-h
laboratory grown culture to the skin of 20 female Swiss mice. No
mortality was observed and there was no evidence of skin inflammation.
Other studies, reviewed by McClintock et al. (1995), indicate
that Bt was not toxic or pathogenic to rabbits following dermal
exposure to various Bt subspecies at doses of up to 2500 mg/kg. In
some cases, mild irritation was observed.
6.1.4 Dermal scarification exposure
This test evaluates both the potential toxicity and infectivity
of a MPCA. In the case of Bt, toxicity is unlikely due to its mode of
action. However, this test also evaluates the importance of intact
skin in preventing infection by Bt.
Fisher & Rosner (1959) scarified the skin of 4 rabbits, then
applied 2.2 × 106 cfu of a commercial Btk formulation. No skin
inflammation or sign of infection was observed.
De Barjac et al. (1980) applied 3.3 × 1013 cfu of a commercial
Bti formulation to the skin of 6 male New Zealand White rabbits. No
skin inflammation or sign of infection was observed.
6.1.5 Subcutaneous inoculation
This route of exposure is considered a more challenging test of
potential infectivity than oral or dermal exposure, because the
barrier of the skin is breached. However, subcutaneous exposure may
take place only if the skin is damaged by the spraying or is already
otherwise damaged.
De Barjac et al. (1980) subcutaneously inoculated 20 female Swiss
mice and 10 tricolour guinea-pigs, respectively, with 8.5 × 107 cfu
and 1.7 × 108 cfu of a 48-h laboratory-grown Bti culture. There was
no evi